Ripretinib in Advanced Gastrointestinal Stromal Tumors: A Case Series and Literature Review from a Tertiary Cancer Center in India

Abstract

The therapeutic armamentarium for advanced gastrointestinal stromal tumors (GISTs) is rapidly evolving and demands personalized strategies due to its increasing complexity. We are witnessing an expansion of the treatment modalities with new molecules being added to the same. Novel agents such as avapritinib and ripretinib have been granted Food and Drug Administration approval for platelet-derived growth factor α-D842V-mutant and refractory GIST patients, respectively. Ripretinib received its approval in May 2020 for individuals with advanced GIST who had been treated with three or more kinase inhibitors after publication of results of the INVICTUS trial. Here, we share our experience of four patients with previously treated advanced GIST who received ripretinib through an expanded access program. Our favorable experience with ripretinib warrants wider availability and easy accessibility of this drug in India for improving outcomes of patients with GIST.

Keywords

advanced GIST - ripretinib - case series

• References

• 1 Blay JY. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev 2011; 37 (05) 373-384
• 2 Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28 (07) 1247-1253
• 3 Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011; 67 (Suppl 1, Suppl 1): S25-S43
• 4 Demetri GD, van Oosterom AT, Garrett CR. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368 (9544): 1329-1338
• 5 Demetri GD, Reichardt P, Kang YK. et al; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863): 295-302
• 6 Heinrich MC, Jones RL, von Mehren M. et al. Avapritinib in advanced PDGFRA D842V- mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21 (07) 935-946
• 7 Smith BD, Kaufman MD, Lu WP. et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019; 35 (05) 738-751.e9
• 8 Janku F, Abdul Razak AR, Chi P. et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol 2020; 38 (28) 3294-3303
• 9 Blay JY, Serrano C, Heinrich MC. et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo- controlled, phase 3 trial. Lancet Oncol 2020; 21 (07) 923-934
• 10 Zalcberg JR, Heinrich MC, George S. et al. Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist 2021; 26 (11) e2053-e2060
• 11 Bauer S, Jones RL, Blay JY. et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial. J Clin Oncol 2022; 40 (34) 3918-3928
• 12 Kang YK, Ryu MH, Yoo C. et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14 (12) 1175-1182
• 13 Heinrich MC, Jones RL, George S. et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med 2024; 30 (02) 498-506
• 14 George S, Blay JY, Chi P. et al. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations. Future Oncol 2024; 20 (27) 1973-1982